First-Line Immunotherapy Beneficial in Specific Patient Subset with Advanced Lung Cancer – Specialty Pharmacy Times
|
First-Line Immunotherapy Beneficial in Specific Patient Subset with Advanced Lung Cancer
Specialty Pharmacy Times “This study is an important step toward understanding the impact of tumor mutation burden and PD-L1 in immunotherapy response,” said lead investigator David Carbon, MD, PhD. “This data shows we should evaluate these 2 factors independently to most … |
